Navigation Links
Vista Partners Updates Coverage on MediciNova Inc. (NASDAQ: MNOV); Maintains $8.50 Price Target
Date:10/21/2008

LOS ANGELES, Oct. 21 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on MediciNova Inc. (Nasdaq: MNOV) and maintains its $8.50 price. "MediciNova recently announced positive preliminary data on MN-221. MN-221, if approved, will garner a sizable percentage of the asthma market potentially resulting in hundreds of millions of dollars in sales for MediciNova. Medicinova's other clinical candidate, MN-166, is intended for the treatment of multiple sclerosis (MS) and MS is a multi-billion dollar market. As the Company announces additional positive data the value of Medicinova will increase," said Ross Silver, Director of Research for Vista Partners. For more information and to download the FREE report, please visit the Vista Partners website at http://www.vistap.com and click on the download research icon.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About MediciNova, Inc.:

MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmace
'/>"/>

SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
2. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
3. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp.
5. Boston Scientific Agrees To Sell Fluid Management and Venous Access Businesses to Avista Capital Partners for $425 Million
6. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
7. Accipiter Capital Management Opposes Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
8. Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
9. Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners
10. Synvista Therapeutics to Present at the Roth 20th Annual OC Growth Stock Conference
11. Avista Capital Partners Enhances Energy Practice With Appointment of Gerhard Kurz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... SUNDAY, July 13, 2014 (HealthDay News) -- Eye tests ... stages of Alzheimer,s disease, two new studies suggest. ... used a certain eye test found a significant association ... the eye and levels of the plaques in the ... Alzheimer,s disease. This type of eye test could ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July 14, 2014 ... may have bigger brains and sharper thinking skills than their ... connection between playing games such as puzzles, crosswords, cards and ... 60s. Researchers found that people who played those games ... memory and other mental functions. And, based on MRI scans, ...
(Date:7/14/2014)... Many people are unhappy with their ... to reduce a “double chin.” A new product ... to go under the knife. Jawflex is a double ... therefore tightening the skin in that area and reducing ... used for facial exercise, double chin elimination and sagging ...
(Date:7/14/2014)... July 14, 2014 Many diet plans often ... study by the School of Public Health at the University ... had a near-zero effect on weight loss. Now experts are ... with some form of portion control to trigger ... monitoring portions and controlling how much is consumed, simply by ...
(Date:7/14/2014)... Sometimes, thinking “inside the box” can ... its first product release, Joyboxx™ - The world’s only ... , Inventor and CEO, Deborah Semer began designing ... storage solution for their ‘toys’ after she realized no ... industry. , Semer met 30-year industry veteran Phyllis Heppenstall, ...
Breaking Medicine News(10 mins):Health News:Eye Tests Might Help ID Alzheimer's, Studies Suggest 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 3Health News:Passionate Playground launches Joyboxx 2Health News:Passionate Playground launches Joyboxx 3
... Win Patient Safety Protections, OAKLAND, Calif., ... University of California medical centers throughout the ... majority, the California Nurses Association,announced today. The ... as resolving long-standing issues of pension and ...
... serious trauma live, often with little visible damage, surgeons say ... of war in Iraq, there,s some relatively good medical ... are now surviving injuries that would have been fatal in ... The Journal of Craniofacial Surgery , the surgical and treatment ...
... Mich., March 24 Perrigo Company,(Nasdaq: PRGO ... CEO Joseph,C. Papa will present at the 12th ... March 25, at 2:05 p.m. (ET) at the,Grand ... Company is a leading global healthcare supplier that ...
... Fitness,Corporation (OTC Bulletin Board: HFIT) today announced that ... repurchase up to $2.5 million of the,company,s outstanding ... shares on the open market in amounts and ... with Securities and Exchange,Commission Rule 10b-18 and other ...
... urged to discuss risk factors with their doctors, ... long been known that,psoriasis, a chronic skin condition ... bleed, can have a significant negative impact on ... finding that,psoriasis, especially severe psoriasis, is linked with ...
... International,Corporation (Nasdaq: PRXL ) announced today it will ... Conference. James Winschel, Senior Vice,President and Chief Financial Officer ... a.m. ET on Thursday, March 27, 2008., A ... the,"Investor Relations Webcasts" section of PAREXEL,s web site at, ...
Cached Medicine News:Health News:UC RNs Overwhelmingly Approve New Contract 2Health News:UC RNs Overwhelmingly Approve New Contract 3Health News:Innovative Care Is Helping Iraq War's Injured Survive 2Health News:Innovative Care Is Helping Iraq War's Injured Survive 3Health News:Health Fitness Announces $2.5 Million Stock Repurchase Plan 2Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 2Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 3Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 4Health News:PAREXEL International to Present at Bank of America 2008 Smid Cap Conference 2
(Date:7/11/2014)... -- Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI ), ... and Drug Administration ("FDA"), has notified the Company that ... Drug ("IND") application before granting the Company permission to ... Dr. Chris Chapman , RCP,s President, commented, "We ... When we receive the agency,s official comments and/or recommendations, ...
(Date:7/11/2014)... , July 11, 2014 Research ... "Global Hypodermic Needles Market 2014-2018" report to their ... A hypodermic needle is a hollow needle commonly ... body or or to extract fluids from it. A ... or to inject substances that cannot be ingested. Hypodermic ...
(Date:7/11/2014)... On Thursday, July 10, 2014, the NASDAQ ... Average finished the day 0.42% lower at 16,915.07, and the ... broad based as eight out of ten sectors ended the ... ended the day at 711.88, down 0.02%, while the index ... initiated coverage on the following equities: Covidien PLC (NYSE: ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4
... 23, 2012 Event details: ... p.m. Renaissance Palm Springs Hotel ... , CA Ameritox(SM), the nation,s leader in ... emerging trends and technologies in medication monitoring at the American Academy of Pain ...
... , Inc. (Nasdaq: NXTM ), a leading ... of the Chronic Disease Research Group (CDRG) study which ... for daily, or more frequent, home hemodialysis, experienced a ... higher 3-year survival compared with that of patients treated ...
Cached Medicine Technology:Ameritox Provides Educational Support to Clinicians to Help Reduce Opioid Misuse, Abuse and Diversion 2Ameritox Provides Educational Support to Clinicians to Help Reduce Opioid Misuse, Abuse and Diversion 3Data Published in the Journal of the American Society of Nephrology Shows Daily Home Hemodialysis Patients with the NxStage System One Have Significantly Lower Risk of Mortality and Improved 3-Year Survival Versus Patients on Conventional Hemodialys 2Data Published in the Journal of the American Society of Nephrology Shows Daily Home Hemodialysis Patients with the NxStage System One Have Significantly Lower Risk of Mortality and Improved 3-Year Survival Versus Patients on Conventional Hemodialys 3Data Published in the Journal of the American Society of Nephrology Shows Daily Home Hemodialysis Patients with the NxStage System One Have Significantly Lower Risk of Mortality and Improved 3-Year Survival Versus Patients on Conventional Hemodialys 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: